Associated Papers
Amivantamab as a salvage therapy post-EGFR-tyrosine kinase inhibitor failure in patients with mutated EGFR non-small cell lung cancer.
Krayim B et al.
Translational Lung Cancer Research, 2025
Overcoming CEP85L-ROS1, MKRN1-BRAF and MET amplification as rare, acquired resistance mutations to Osimertinib.
Kian W et al.
Frontiers in Oncology, 2023
Select a paper to view details